Lai C, Onnis E, Pirisi R, Orani E, Delogu G, Cherchi A
Institute of Cardiology, University of Cagliari, Italy.
Drugs Exp Clin Res. 1988;14(11):699-705.
To assess the anti-anginal and anti-ischaemic activity of the beta-blocker atenolol (ATN) and the calcium antagonist nifedipine (NIFE) and their combination in coronary patients, a double-blind, cross-over, placebo-controlled study was performed. Ten male patients (mean age: 58 +/- 2.9 years) suffering from a stable effort angina were studied. The study lasted 14 weeks: after 2 weeks of wash-out, patients were randomly assigned to ATN (100 mg/day) and placebo-NIFE, or placebo-ATN and NIFE (10 mg three times/day), or ATN (100 mg) plus NIFE (10 mg three times/day) for 4 weeks. Maximal symptom-limited stress tests on a bicycle (10 watt/min) during the wash-out period (on days 10 and 14) and at the end of each treatment period were performed. All treatments significantly increased the work load at 1 mm ST depression, the angina threshold and the total work, and reduced ST depression at the maximal common work and at the maximal work. Also the atenolol-nifedipine combination significantly reduced ST depression at maximal common work and maximal work as compared to ATN and NIFE alone. In conclusion, this study confirms the anti-ischaemic and anti-anginal activity of both atenolol and nifedipine in stable effort angina and shows that their combination is able to increase anti-ischaemic activity.
为评估β受体阻滞剂阿替洛尔(ATN)和钙拮抗剂硝苯地平(NIFE)及其联合用药在冠心病患者中的抗心绞痛和抗缺血活性,进行了一项双盲、交叉、安慰剂对照研究。研究了10例患有稳定劳力性心绞痛的男性患者(平均年龄:58±2.9岁)。研究持续14周:在2周的洗脱期后,患者被随机分配接受阿替洛尔(100毫克/天)和安慰剂-硝苯地平,或安慰剂-阿替洛尔和硝苯地平(10毫克,每日三次),或阿替洛尔(100毫克)加硝苯地平(10毫克,每日三次),治疗4周。在洗脱期(第10天和第14天)以及每个治疗期结束时,进行了症状限制的最大自行车运动试验(10瓦/分钟)。所有治疗均显著增加了ST段压低1毫米时的工作量、心绞痛阈值和总工作量,并降低了最大常见工作量和最大工作量时的ST段压低。与单独使用阿替洛尔和硝苯地平相比,阿替洛尔-硝苯地平联合用药在最大常见工作量和最大工作量时也显著降低了ST段压低。总之,本研究证实了阿替洛尔和硝苯地平在稳定劳力性心绞痛中的抗缺血和抗心绞痛活性,并表明它们的联合用药能够增强抗缺血活性。